Vanguard Group Inc Amylyx Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,223,968 shares of AMLX stock, worth $21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,223,968

Previous 5,348,139 21.02%

Holding current value

$21 Million

Previous $15.2 Million 47.16%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.62 - $2.71 $1.82 Million - $3.05 Million	-1,124,171 Reduced 21.02%	4,223,968 $8.03 Million
Q1 2024 May 10, 2024	BUY	$2.71 - $19.57 $196,672 - $1.42 Million	72,573 Added 1.38%	5,348,139 $15.2 Million
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $2.72 Million - $4.16 Million	225,486 Added 4.46%	5,275,566 $77.7 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $2.25 Million - $2.91 Million	124,188 Added 2.52%	5,050,080 $92.5 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $3.75 Million - $5.61 Million	178,551 Added 3.76%	4,925,892 $106 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $10.8 Million - $15.9 Million	388,849 Added 8.92%	4,747,341 $139 Million
Q4 2022 Feb 10, 2023	BUY	$29.75 - $39.26 $25.1 Million - $33.1 Million	844,136 Added 24.02%	4,358,492 $161 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $43.2 Million - $77.9 Million	2,520,355 Added 253.56%	3,514,356 $98.9 Million
Q2 2022 Aug 12, 2022	BUY	$6.85 - $19.93 $12,419 - $36,133	1,813 Added 0.18%	994,001 $19.1 Million
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $12.7 Million - $32.6 Million	992,188 New	992,188 $12.8 Million

Others Institutions Holding AMLX

# of Institutions

139

Shares Held

46.5M

Call Options Held

226K

Put Options Held

909K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Amylyx Pharmaceuticals, Inc. Transaction History